-
Oral DMT for Sickle Cell Showing Safety, Potential Efficacy in Phase 1 Trial
FT-4202, a potential oral disease-modifying treatment for SCD, has a favorable safety profile and effects that support efficacy; a larger study is planned. Read more about it here.
What do you think of this news?
-
1 Reply
-
really it’s a great news, thank you.
Log in to reply.